Johnson & Johnson launches clinical trial for Ebola vaccine in Sierra Leone
This is the first study that will focus on Janssen’s prime-boost vaccine regimen within a country involved in the Ebola outbreak. This trial will be launched simultaneously with several ongoing Phase I and II studies that are taking place in Europe, the U.S. and Africa. Together, these studies are individual pieces of an overall plan to speed the development of an Ebola vaccine regimen.
This trial marks a significant milestone for Johnson & Johnson, as the company only expanded on its commitment to fight Ebola just one year ago.
"Never again can Ebola be allowed to cause the human suffering that the world has witnessed in West Africa, and we remain committed as ever to helping the international community combat this disease," Paul Stoffels, M.D., chief scientific officer and worldwide chairman, Pharmaceuticals, Johnson & Johnson, said. "One of the many lessons learned from the outbreak is we cannot let our guard down with Ebola, and we need to test every promising prevention tool. It is our hope that this study will help to confirm the value of this vaccine regimen in Ebola control efforts -- not just for Sierra Leone, but for the world."